See accompanying notes to consolidated financial statements.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Malaysia, Singapore and Thailand; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.
Basis of Presentation
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2022 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 3, 2023.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents
The Company maintains substantially all of its cash balances at several institutions located in the United States, Hong Kong and China which at times may exceed insured limits. As of March 31, 2023, there was $803,000 and $1.8 million in bank accounts located in the United States and Hong Kong, respectively, in excess of insured limits. As of March 31, 2023, cash and cash equivalents included $4.1 million held in bank accounts located in China subject to foreign currency controls. The Company has not experienced any losses on such accounts. See Note 4 for additional information regarding the Company's investments in cash equivalents held in brokerage accounts. The Company believes that it is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash and cash equivalents are held.
Net Income (Loss) Per Common Share
Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.
The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):
| | Three Months Ended March 31, | |
| | 2023 | | | 2022 | |
| | Income (Numerator) | | | Shares (Denominator) | | | Per Share Amount | | | Loss (Numerator) | | | Shares (Denominator) | | | Per Share Amount | |
Basic net income (loss) per common share: | | | | | | | | | | | | | | | | | | | | | | | | |
Net income (loss) available to common stockholders | | $ | 257 | | | | 11,424 | | | $ | 0.02 | | | $ | (105 | ) | | | 11,254 | | | $ | (0.01 | ) |
Effect of dilutive securities: | | | | | | | | | | | | | | | | | | | | | | | | |
Non-vested restricted stock | | | — | | | | 4 | | | | | | | | — | | | | — | | | | | |
Diluted net income (loss) per common share: | | | | | | | | | | | | | | | | | | | | | | | | |
Net income (loss) available to common stockholders plus assumed dilution | | $ | 257 | | | | 11,428 | | | $ | 0.02 | | | $ | (105 | ) | | | 11,254 | | | $ | (0.01 | ) |
In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 169,690 shares were not included for the three months ended March 31, 2022.
Recent Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB Accounting Standards Codification (“ASC”). In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326. ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022. The adoption of this standard did not have a material impact on the Company's financial statements.
Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
2. REVENUE
Revenue Recognition
All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 4% of sales. Sales returns were 1% of sales for each of the three months ended March 31, 2023 and 2022. No material changes in estimates have been recognized during the periods presented. See Note 3 for additional information.
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
Deferred Revenue
The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. As of March 31, 2023 and 2022, the Company had $3.9 million of contract liabilities where performance obligations have not yet been satisfied. The Company expects to satisfy its remaining performance obligations and recognize the revenue within the next twelve months.
Disaggregation of Revenue
The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider. See Note 11 for revenue by market information.
The Company’s net sales by product and service are as follows (in thousands):
| | Three Months Ended March 31, | |
| | 2023 | | | 2022 | |
Product sales | | $ | 11,048 | | | $ | 10,322 | |
Administrative fees, freight and other | | | 845 | | | | 1,257 | |
Less: sales returns | | | (32 | ) | | | (33 | ) |
Total net sales | | $ | 11,861 | | | $ | 11,546 | |
Concentration
No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three months ended March 31, 2023 and 2022. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.
Arrangements with Multiple Performance Obligations
The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.
Practical Expedients
The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.
The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.
3. BALANCE SHEET COMPONENTS
The components of certain balance sheet amounts are as follows (in thousands):
|
|
March 31, 2023 |
|
|
December 31, 2022 |
|
Cash, cash equivalents and restricted cash: |
|
|
|
|
|
|
|
|
Cash |
|
$ |
11,460 |
|
|
$ |
12,834 |
|
Cash equivalents |
|
|
55,150 |
|
|
|
56,833 |
|
|
|
|
66,610 |
|
|
|
69,667 |
|
Restricted cash |
|
|
38 |
|
|
|
79 |
|
|
|
$ |
66,648 |
|
|
$ |
69,746 |
|
Inventories: |
|
|
|
|
|
|
|
|
Finished goods |
|
$ |
4,023 |
|
|
$ |
3,653 |
|
Raw materials |
|
|
992 |
|
|
|
890 |
|
Reserve for obsolescence |
|
|
(33 |
) |
|
|
(18 |
) |
|
|
$ |
4,982 |
|
|
$ |
4,525 |
|
Other accrued expenses: |
|
|
|
|
|
|
|
|
Sales returns |
|
$ |
89 |
|
|
$ |
70 |
|
Employee-related expense |
|
|
508 |
|
|
|
737 |
|
Warehousing, inventory-related and other |
|
|
508 |
|
|
|
374 |
|
|
|
$ |
1,105 |
|
|
$ |
1,181 |
|
Deferred revenue: |
|
|
|
|
|
|
|
|
Unshipped product and unredeemed product vouchers |
|
$ |
3,880 |
|
|
$ |
3,822 |
|
Auto ship advances |
|
|
1,737 |
|
|
|
1,775 |
|
|
|
$ |
5,617 |
|
|
$ |
5,597 |
|
4. FAIR VALUE MEASUREMENTS
As of March 31, 2023, cash and cash equivalents include the Company’s investments in money market funds and corporate debt securities. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at March 31, 2023 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income (expense). Realized gains and losses, as well as interest income, are also included in other income (expense). The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.
The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value. The Company has elected to not fair value existing eligible items.
Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):
| | | March 31, 2023 | | | December 31, 2022 | |
| Fair Value Level1 | | Adjusted Cost | | | Gross Unrealized Losses | | | Fair Value | | | Adjusted Cost | | | Gross Unrealized Losses | | | Fair Value | |
Money market funds | Level 1 | | $ | 7,622 | | | $ | — | | | $ | 7,622 | | | $ | 2,143 | | | $ | — | | | $ | 2,143 | |
Government and municipal debt securities | Level 2 | | | — | | | | — | | | | — | | | | 6,759 | | | | — | | | | 6,759 | |
Corporate debt securities | Level 2 | | | 47,547 | | | | (19 | ) | | | 47,528 | | | | 47,947 | | | | (16 | ) | | | 47,931 | |
Total investments | | $ | 55,169 | | | $ | (19 | ) | | $ | 55,150 | | | $ | 56,849 | | | $ | (16 | ) | | $ | 56,833 | |
1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
As of March 31, 2023, the Company's unrealized losses result from investments in an unrealized loss position for less than 12 months. The gross unrealized losses related to these investments were primarily driven by factors other than credit risk, including market risk. The Company anticipates that it will recover the entire amortized cost basis of such available-for-sale debt securities and has determined that no allowance was required to be recognized during the three months ended March 31, 2023 and 2022.
5. LEASES
The Company leases 7,300 square feet of office space in Hong Kong with a term expiring in June 2026, and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff with a term expiring in September 2030. To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2024 and December 2028, respectively.
The Company leases seven branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Malaysia, Singapore, Thailand, India and the Cayman Islands. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.
The components of lease cost were as follows (in thousands):
|
|
Three Months Ended March 31, |
|
|
|
2023 |
|
|
2022 |
|
Operating leases |
|
$ |
330 |
|
|
$ |
334 |
|
Short-term leases |
|
|
37 |
|
|
|
46 |
|
Total lease cost |
|
$ |
367 |
|
|
$ |
380 |
|
Cash paid for amounts included in the measurement of operating leases liabilities was $345,000 and $322,000 for the three months ended March 31, 2023 and 2022, respectively.
The weighted-average remaining lease term and discount rate related to operating leases as of March 31, 2023 were as follows:
Weighted-average remaining lease term (in years) |
|
|
4.8 |
|
Weighted-average discount rate |
|
|
4.2 |
% |
As most of our leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.
The annual scheduled lease payments of our operating lease liabilities as of March 31, 2023 were as follows (in thousands):
Remainder of 2023 |
|
$ |
909 |
|
2024 |
|
|
1,022 |
|
2025 |
|
|
963 |
|
2026 |
|
|
579 |
|
2027 |
|
|
299 |
|
Thereafter |
|
|
679 |
|
Total lease payments |
|
|
4,451 |
|
Less: imputed interest |
|
|
(424 |
) |
Present value of lease liabilities |
|
$ |
4,027 |
|
For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.
6. INCOME TAXES
The effective income tax rate for the three months ended March 31, 2023 includes estimates for foreign income inclusions such as global intangible low-taxed income (“GILTI”) and Subpart F income. As of March 31, 2023, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of March 31, 2023, the Company has a valuation allowance against deferred tax assets in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.
As a result of return to provision adjustments, the Company does not expect to have any U.S. federal net operating loss available for carryover beyond the year ending December 31, 2023. The Company has post-apportioned U.S. state net operating loss carryforwards of $438,000 that begin expiring in 2038. At March 31, 2023, the Company has foreign net operating loss carryforwards of approximately $1.4 million in various jurisdictions with various expirations.
As of March 31, 2023, income taxes payable for the repatriation tax on the deemed repatriation of deferred foreign income required by the U.S. Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government, totaled $12.1 million, of which $9.1 million is reflected as a noncurrent liability.
As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings not deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of March 31, 2023, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of March 31, 2023 have already been repatriated. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of March 31, 2023.
The Company and its subsidiaries file tax returns in the United States, California, New Jersey, Texas and various foreign jurisdictions. The Company is no longer subject to state income tax examinations for years prior to 2018. The Company is not aware of any jurisdiction that is currently examining any of its income tax returns.
7. COMMITMENTS AND CONTINGENCIES
The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice. The employment agreements entered into with the management team contain provisions that guarantee the payment of specified amounts in the event of a change in control (together with a termination without cause), as defined, or if the employee is otherwise terminated without cause, as defined, or terminates employment for good reason, as defined.
8. STOCK-BASED INCENTIVE PLANS
Restricted Stock
At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At March 31, 2023, 1,121,683 shares remained available for issuance under the 2016 Plan.
On February 6, 2023, the Company granted 97,900 shares of restricted common stock to certain of its employees. The shares vest in equal parts on a quarterly basis over the next three years and are subject to forfeiture in the event of an employee's termination of service to the Company under specified circumstances.
The following table summarizes the Company’s restricted stock activity under the
2016 Plan:
|
|
Shares |
|
|
Wtd. Avg. Price at Date of Issuance |
|
Nonvested at December 31, 2022 |
|
|
— |
|
|
$ |
— |
|
Granted |
|
|
97,900 |
|
|
$ |
4.84 |
|
Vested |
|
|
(8,162 |
) |
|
$ |
4.84 |
|
Nonvested at March 31, 2023 |
|
|
89,738 |
|
|
$ |
4.84 |
|
Share-based compensation expense of $46,000 was recognized during the three months ended March 31, 2023. As of March 31, 2023, total unrecognized share-based compensation expense related to non-vested restricted stock was $427,000, which is expected to be recognized over a weighted-average period of 1.5 years.
Phantom Equity
On March 15, 2021, the Company’s Board of Directors approved and adopted a Phantom Equity Plan (the “Phantom Plan”). Under the terms of the Phantom Plan, the Board of Directors' Compensation Committee may grant to the Company’s employees, officers, directors, contractors, consultants, or advisors awards of phantom shares entitling grantees the right to receive a cash payment equal to the fair market value of an equal number of shares of the Company’s common stock upon the close of a vesting period, subject to any maximum payment value that the Compensation Committee may set. The vesting of phantom shares is subject to such vesting conditions as the Compensation Committee may specify in a grantee’s award agreement. Grantees of phantom shares shall not by virtue of their receipt of phantom shares have any ownership rights in shares of the Company’s common stock. The Phantom Plan shall continue for a period of ten years, after which no further phantom shares may be awarded (although any phantom shares awarded prior to the expiration of such 10-year period shall be unaffected by the termination of the Phantom Plan).
Also on March 15, 2021, awards for 223,307 phantom shares were granted to the Company’s employees and its non-employee directors. The phantom shares vested in eight equal three-month vesting increments, subject to the satisfaction of both a time-based vesting condition and a performance vesting condition. Both of these vesting conditions were deemed satisfied on the grant date for the initial vesting increment, and were satisfied for each of the following three vesting periods in 2021 and the first vesting period in 2022. The time-based vesting condition was also satisfied for the final three vesting periods in 2022. In order for the time-based vesting condition to be satisfied for each vesting period, the grantee must have remained continuously employed by, or be otherwise continuously providing services to, the Company through the end of the vesting period, and in order for the performance vesting condition to be satisfied for each performance period, the performance criteria designated by the Compensation Committee must have been satisfied. The initial performance vesting condition to be applied to measure performance for the period between March 15, 2021 and June 15, 2021 was designated by the Compensation Committee on or before April 14, 2021, and applied to all future performance periods unless the Compensation Committee elected to change the performance vesting condition on a prospective basis. Future changes to the performance vesting condition must have been made on or before the fifteenth day of any future performance period. If either vesting condition was not satisfied for a vesting date, then the phantom shares scheduled to vest on such date would be forfeited. These phantom shares were subject to a maximum payment value of $12.00 per phantom share. An additional award with similar vesting conditions for 9,074 phantom shares was granted on May 14, 2021 to the Company's new non-employee director, while unvested 9,074 phantom shares granted to the Company's departing non-employee director were forfeited on or about the same date. On each of May 23, 2022, August 31, 2022, and November 25, 2022 the Compensation Committee determined to amend the outstanding awards to provide that the performance criteria shall be deemed satisfied for the three-month performance periods relating to the June 15, 2022, September 15, 2022 and December 15, 2022 vesting dates, respectively. In making its determination, the Compensation Committee noted that the fact that the performance criteria were not achieved for the relevant performance periods was due to extraordinary business circumstances in China that were clearly beyond the Company’s control. The phantom shares awarded in 2021 are now fully vested.
On February 7, 2023, the Company granted 212,937 phantom shares to certain of the Company’s employees and its non-employee directors. The phantom shares vest in eight equal three-month vesting increments, subject to the satisfaction of both a time-based vesting condition and a performance vesting condition. Both of these vesting conditions were deemed satisfied on the grant date for the initial vesting increment. In order for the time-based vesting condition to be satisfied for each vesting period, the grantee must remain continuously employed by, or be otherwise continuously providing services to, the Company through the end of the vesting period, and in order for the performance vesting condition to be satisfied for each performance period, the performance criteria designated by the Compensation Committee must be satisfied. The initial performance vesting condition will be designated by the Compensation Committee and will apply to all future performance periods, unless the Compensation Committee elects to change the performance vesting condition on a prospective basis. Future changes to the performance vesting condition must be made on or before the fifteenth day of any future performance period. If either vesting condition is not satisfied for a vesting date, then the phantom shares scheduled to vest on such date will be forfeited. These phantom shares are subject to a maximum payment value of $12.00 per phantom share.
The phantom share awards are accounted for as liabilities in accordance with FASB ASC Topic
718,
Compensation –
Stock Compensation since they require cash settlement. The grant date of each vesting increment will be established when the Company and the grantees reach a mutual understanding of the key terms and conditions of an award, which is the date upon which each performance vesting condition is communicated to the grantees. Compensation expense is recognized over the requisite service period if it is probable that the performance vesting condition will be achieved. The fair value of the liability incurred is remeasured at the end of each reporting period with any changes in fair value recognized as compensation expense over the requisite service period.
Awards totaling 26,617 and 27,913 phantom shares vested during each of the three months ended March 31, 2023 and 2022, resulting in compensation expense of $127,000 and $196,000 during the three months ended March 31, 2023 and 2022, respectively, related to their cash settlement.
9. STOCKHOLDERS’ EQUITY
Dividends
The Company declared and paid cash dividends of $0.20 per common share during the first quarter of 2023 and 2022, totaling $2.3 million each quarter. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.
Stock Repurchases
On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Any repurchases will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of March 31, 2023, $21.9 million of the $70.0 million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.
Accumulated Other Comprehensive Loss
The changes in accumulated other comprehensive loss by component for the first three months of 2023 were as follows (in thousands):
| | Foreign Currency Translation Adjustments | | | Unrealized Losses on Available-For-Sale Investments | | | Total | |
Balance, December 31, 2022 | | $ | (988 | ) | | $ | (16 | ) | | $ | (1,004 | ) |
Other comprehensive loss | | | (97 | ) | | | (3 | ) | | | (100 | ) |
Balance, March 31, 2023 | | $ | (1,085 | ) | | $ | (19 | ) | | $ | (1,104 | ) |
10. RELATED PARTY TRANSACTIONS
The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a former director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Brunde E. Broady, also a former director of the Company and daughter of Mr. Broady, is the President and Chief Executive Officer of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. The Company recognized royalties of $11,000 and $13,000 during the three months ended March 31, 2023 and 2022, respectively, under this agreement. The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. The agreement terminates March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.
11. SEGMENT INFORMATION
The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).
The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income is adjusted for certain direct costs and commission allocation.
The Company’s operating information by geographic area are as follows (in thousands):
|
|
Three Months Ended March 31, |
|
|
|
2023 |
|
|
2022 |
|
Net sales: |
|
|
|
|
|
|
|
|
Primary Reporting Segment |
|
$ |
11,331 |
|
|
$ |
10,877 |
|
China |
|
|
416 |
|
|
|
481 |
|
Russia and Kazakhstan |
|
|
114 |
|
|
|
188 |
|
Total net sales |
|
$ |
11,861 |
|
|
$ |
11,546 |
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations: |
|
|
|
|
|
|
|
|
Primary Reporting Segment |
|
$ |
1,827 |
|
|
$ |
1,915 |
|
China |
|
|
(20 |
) |
|
|
8 |
|
Russia and Kazakhstan |
|
|
(58 |
) |
|
|
(47 |
) |
Income from operations for reportable segments, net |
|
|
1,749 |
|
|
|
1,876 |
|
Unallocated corporate expenses |
|
|
(2,143 |
) |
|
|
(2,259 |
) |
Other income, net |
|
|
681 |
|
|
|
110 |
|
Income (loss) before income taxes |
|
$ |
287 |
|
|
$ |
(273 |
) |
The Company’s net sales by geographic area are as follows (in thousands):
|
|
Three Months Ended March 31, |
|
|
|
2023 |
|
|
2022 |
|
Net sales from external customers: |
|
|
|
|
|
|
|
|
United States |
|
$ |
279 |
|
|
$ |
256 |
|
Canada |
|
|
170 |
|
|
|
137 |
|
Peru |
|
|
327 |
|
|
|
482 |
|
Hong Kong1 |
|
|
9,673 |
|
|
|
8,776 |
|
China |
|
|
416 |
|
|
|
481 |
|
Taiwan |
|
|
454 |
|
|
|
569 |
|
Japan |
|
|
82 |
|
|
|
235 |
|
Malaysia and Singapore |
|
|
85 |
|
|
|
125 |
|
Russia and Kazakhstan |
|
|
114 |
|
|
|
188 |
|
Europe |
|
|
186 |
|
|
|
201 |
|
Other foreign countries |
|
|
75 |
|
|
|
96 |
|
Total net sales |
|
$ |
11,861 |
|
|
$ |
11,546 |
|
1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K.
12. SUBSEQUENT EVENT
On May 1, 2023, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on May 26, 2023 to stockholders of record on May 16, 2023. The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.